ArticleOsteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA2026
Impact of a national reimbursement add-on policy on refracture risk and secondary fracture prevention after hip fracture in Japan: a population-based interrupted time series analysis.
Article in Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
In Japan, a national reimbursement add-on for secondary fracture prevention after hip fracture surgery, implemented on April 1, 2022, was associated with lower 1-year refracture risk and higher early uptake of post-fracture DXA assessment within 90 days and anti-osteoporosis medication initiation within 120 days, but not with improved 1-year post-fracture treatment persistence. PURPOSE: To assess whether the Japanese national reimbursement add-on policy for preventing secondary fracture after hip fracture surgery, introduced in April 2022, was associated with actual changes in refracture risk and key secondary fracture prevention care processes after hip fracture surgery.
methodsWe conducted a population-based interrupted time-series analysis using longitudinal health insurance claims data collected in Japan between 2019 and 2023. Participants were adults aged ≥ 50 years with newly identified and surgically treated hip fracture. The intervention was implementation of the policy on 1 April 2022. Outcome measures were absolute changes 12 months after policy implementation in the 1-year cumulative risk of first refracture, 90-day cumulative probability of receiving dual-energy X-ray absorptiometry (DXA) assessment, 120-day cumulative probability of initiating anti-osteoporosis medication, and 1-year post-fracture treatment persistence.
resultsTwelve months after policy implementation, the absolute effect on the 1-year cumulative risk of refracture in the hip fracture series was - 1.02 percentage points (95% confidence interval, - 1.44 to - 0.60). The absolute effects on early care processes were 41.37 percentage points (40.21 to 42.54) for DXA assessment and 22.83 percentage points (21.70 to 23.95) for the initiation of anti-osteoporosis medication. The absolute effect on 1-year post-fracture treatment persistence was - 6.76 percentage points (- 10.04 to - 3.49).
conclusionsThe reimbursement add-on policy for secondary fracture prevention after hip fracture surgery was associated with a lower 1-year cumulative refracture risk and a higher cumulative probability of receiving DXA assessment and initiating anti-osteoporosis medication, but not with improved 1-year post-fracture treatment persistence. Strategies supporting sustained follow-up and reengagement may be needed.
Indexed as
Identifiers
42008165What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.